BIOPHARMA
Transforming ECG technology in clinical trials
Transforming ECG technology in clinical trials
3.3+
million users
250+
million ECGs recorded
25+
countries with clinical studies powered by our ECG solutions
200+
clinical publications validating clinical utility
At the heart of clinical research and widely adopted across various therapeutic areas, from small biotechs and academia to large pharmaceutical companies and registrational trials, AliveCor's solutions set new standards for efficiency, accuracy, and patient engagement in cardiac monitoring.
Power your sponsors with technology trusted by industry leaders and researchers worldwide. Gain and deliver proven expertise in cardiac health management and leverage AliveCor's patient-centric, cost-effective, and reliable solutions.
Over 80% of clinical trials do not reach their recruitment targets within their specified timeframe, creating trial delays and increased costs.1,2 CROs have opportunities and imperatives in leveraging digital health technologies.
Our solutions are designed for patients, appealing to a broader demographic from the ease of use and reliability, demonstrating faster patient recruitment and higher adherence3,4 in decentralized, hybrid, and traditional clinical trials. Remote ECG data is delivered and streamlined with EHR, API, and SDK data integration options or our proprietary platform.
Adopting AliveCor's ECG technology enables CROs to achieve:
Clinical Quality QT** Determinations
High-quality, instant, and automated QT determination readings for QT interval analysis
Real-Time ECG Data Collection Across your Team, Sponsors, and Sites
Instant capture and transmission of ECG data, ensuring data quality and patient safety
Data Integration with any Global EDC
Seamlessly integrate with other clinical systems for comprehensive patient overview
Remote Monitoring
Portability facilitates hybrid trials, reducing patient burden and expanding recruitment possibilities
AFib Monitoring in DCT
DeTAP Study evaluated oral anticoagulation therapy for Atrial Fibrillation (Afib).
Remote monitoring of 100 participants in single-arm trial design with KardiaMobile 6L demonstrated:
QT Interval Monitoring in DCT
Study 4evaluated efficacy of COVID-19 treatment required cardiac safety monitoring of the QT interval.
Multi-center randomized clinical trial was fully remote, monitored the QT interval for 231 participants (3,256 ECGs), and demonstrated:
Our Clinical Research Partners
AliveCor works with some of the leading companies, including:
AliveCor is more than a partner. Together, we are leaders in the charge for patient-centered healthcare innovation. Their 6L EKG device is a key part of Medidata’s Sensor Cloud program and their cardiac monitoring technology empowers us to design clinical trials that are more efficient, cost-effective, and more beneficial for patients.
AliveCor's technology equips our sponsors and CROs to collect essential heart data and QT information, which is critical in drug development. It supports a greater patient experience and confidence which translates into greater success in our trials. Working with AliveCor, we meet the real-world needs of patients and caregivers, driving tangible improvements in healthcare outcomes and research efficacy.
SVP, Head of Patient Cloud, Medidata
Overview for CROs
Overview for CROs
Choose AliveCor for your clinical trials.
Connect with us for a custom integration strategy that sets your research apart.
Disclaimers
1*KardiaMobile 6L does not check for heart attack.
**QT measurements made using EK12 ECG algorithm.
1. Huang GD, et al. Contemporary Clinical Trials March 2018(66) pp 74-79.
2. Chaudhari N et al. Perspect Clin Res. 2020 Apr-Jun; 11(2): 64-69.
3. Sarraju A et al. Npj Digital Medicine (2022)5:80.
4. Mayfield JJ et al. Commun Med (Lond). 2021 Dec 20;1:62.